Literature DB >> 16184054

Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.

S Tariq Sadiq, Salim Fredericks, Saye H Khoo, Phillip Rice, David W Holt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16184054     DOI： 10.1097/01.aids.0000186828.99032.60

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.

Authors:  Mohammad M Hossain; Michael A Parniak
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Efavirenz use during pregnancy and for women of child-bearing potential.

Authors:  Matthew F Chersich; Michael F Urban; Francois W D Venter; Tina Wessels; Amanda Krause; Glenda E Gray; Stanley Luchters; Dennis L Viljoen
Journal:  AIDS Res Ther       Date:  2006-04-07       Impact factor: 2.250

3.  Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.

Authors:  HariOm Singh; Sonam Lata; T N Dhole; Raman R Gangakhedkar
Journal:  Mol Genet Genomic Med       Date:  2019-03-12       Impact factor: 2.183

4.  Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Authors:  Tim R Cressey; Hannah Green; Saye Khoo; Jean-Marc Treluyer; Alexandra Compagnucci; Yacine Saidi; Marc Lallemant; Diana M Gibb; David M Burger
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

5.  German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

Authors:  Bernd Buchholz; Matthias Beichert; Ulrich Marcus; Thomas Grubert; Andrea Gingelmaier; Annette Haberl; Brigitte Schmied
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

6.  Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

Authors:  Alessandro Schipani; David Back; Andrew Owen; Gerry Davies; Saye Khoo; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.